• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Kenya becomes first African country to join the Dengue Alliance

Home > Press releases

Kenya becomes first African country to join the Dengue Alliance

Nairobi, Kenya / Kuala Lumpur, Malaysia — 27 Oct 2026

Kenya has become the first African country to join the Dengue Alliance, with the Kenya Medical Research Institute (KEMRI) becoming part of the global partnership dedicated to advancing dengue treatment research. The country’s entry into the Alliance was formally announced during its meeting held on 27 October in Kuala Lumpur, Malaysia.

Established in 2022, the Dengue Alliance brings together research institutions in dengue-endemic countries to accelerate the development of safe, effective, affordable, and accessible treatments for dengue. Its membership includes the Drugs for Neglected Diseases initiative (DNDi) and research institutions from Brazil, Malaysia, India, and Thailand, with Kenya now joining the international collaboration.

‘Dengue is a growing public health concern in Africa, but its true burden remains underestimated due to underdiagnosis and underreporting. Through the Dengue Alliance, KEMRI will contribute African expertise and evidence to strengthen global efforts to advance dengue research, surveillance, diagnostics, and clinical management,’ said Dr Erick Muok, Acting Director of Research and Development at KEMRI.

This new membership will expand the geographic and scientific reach of the Alliance, creating new avenues for dengue research on much-needed treatments, and ensure patients from the African continent are prioritized in future studies.

‘We are pleased to welcome KEMRI to the Dengue Alliance. Their expertise in clinical research, diagnostics, surveillance, and outbreak response will help ensure dengue research responds to the needs of affected populations in Africa,’ said Dr André Siqueira, Head of the Global Dengue Programme at DNDi.

‘Dengue is no longer a disease confined to traditionally endemic regions, and addressing it requires global cooperation. While we have seen important advancements in vaccines and vector control, there is still no specific treatment for dengue and more research is needed to close this critical gap,’ he added.

The expansion of the Dengue Alliance comes amid growing concerns about dengue as an emerging public health threat in Africa, where there is increasing consensus that the burden is substantially underestimated.

Kenya is also experiencing an expanding dengue epidemiological footprint. All four dengue virus serotypes have been detected in the country since its first reported epidemic in 1982, and recent dengue transmission has been reported beyond traditionally affected coastal areas, including northern and western Kenya, as well as areas bordering Uganda, South Sudan, and Ethiopia.

According to the WHO, from January to August 2026, Kenya had reported almost 10,000 cases, representing a substantial increase from the 4,300 cases reported in 2025, and 1,400 cases reported in 2024.

Recent DNDi-led epidemiological studies in Senegal, Ghana, and the Democratic Republic of the Congo (DRC) have revealed that dengue transmission in Africa is also more widespread than previously recognized. This underreported burden can hinder timely diagnosis, outbreak preparedness, and effective allocation of resources for prevention and control. Detailed results from these studies are expected to be published in early 2027 and will contribute to a stronger evidence base for dengue policy and decision-making in Africa.

Alliance partners are also working to address the lack of specific treatments for the disease. Through a collaboration between DNDi and the Serum Institute of India, partners are progressing a promising dengue treatment candidate into a Phase III clinical trial expected to begin in early 2027 in Brazil, Thailand, and Malaysia. The Alliance is also supporting research on additional treatment approaches, including antivirals and host-directed therapies.

Through its expertise in arboviral diseases, clinical research, diagnostics, surveillance, and climate-related health research, KEMRI will contribute to Alliance efforts to strengthen understanding of dengue transmission, improve diagnosis, and support the development of new medicines for affected populations.

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit medical research organization that discovers, develops, and delivers safe, effective, and affordable treatments for neglected populations. DNDi is developing medicines for sleeping sickness, leishmaniasis, Chagas disease, parasitic worm diseases, mycetoma, dengue, cryptococcal meningitis, hepatitis C, and viruses of pandemic potential. Its research priorities include children’s health, gender equity and gender-responsive R&D, and diseases impacted by climate change. Since its creation in 2003, DNDi has collaborated with public and private partners worldwide to deliver 17 new treatments for six deadly diseases, saving millions of lives. dndi.org

About KEMRI

The Kenya Medical Research Institute, a State Corporation established pursuant to the Kenya Medical Research Institute Charter as a health research institution with specialized degree awarding status in accordance with section 24(1)(a) of the Universities Act, whose registered offices are located at KEMRI Headquarters, Off Raila Odinga Way and of P.O. Box 54840 -00200 Nairobi.

Media contacts

Linet Otieno (Nairobi)

Mobile: +254 733 624206

latieno@dndi.org

Frédéric Ojardias (Geneva)

Mobile: +41 79 431 6216

fojardias@dndi.org

Photo credit: Lameck Ododo-DNDi

Evidence for impact Translational research Clinical trials Climate change Partnership Dengue Africa Asia Latin America

Read, watch, share

Loading...
Publications
6 Nov 2026

Extreme heat and climate-sensitive infectious diseases

News
2 Nov 2026

Project to develop dengue treatment pre-selected by the Global Coalition for Local and Regional Production, Innovation, and Equitable Access

close up of a scientist holding tools they are wearing blue gloves
Press releases
29 Oct 2026

DNDi welcomes GHIT Fund’s support for innovative approaches to improve success in Chagas disease drug discovery with Nagasaki University, the University of Dundee, and Eisai 

News
9 Oct 2026

DNDi 2026 Projects of the Year recognize teams and partners for their work to advance an open-science antiviral for future coronavirus pandemics and a single-dose treatment for sleeping sickness

Press releases
6 Oct 2026

Ghana’s KNUST and DNDi partner to accelerate drug discovery for neglected diseases in Africa

Statements
25 Sep 2026

DNDi intervention at the UN High-Level Meeting on Pandemic Prevention, Preparedness, and Response at the 81st UN General Assembly

News
15 Sep 2026

New DNDi report: Implementing Article 9.5 of the WHO Pandemic Agreement – building on current policy and practice for publicly funded R&D

Hand with lap glove holding a sample with transparent liquid
Publications
8 Sep 2026

Implementing Article 9.5 of the WHO Pandemic Agreement

VIEW ALL

Help neglected patients

To date, we have delivered seventeen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license